Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Announces 1-for-20 Reverse Stock Split

NEW YORK — OpGen said on Wednesday that it is planning a 1-for-20 reverse stock split in order to regain compliance with the Nasdaq's minimum bid price listing requirement of $1.00 per share.

The reverse stock split, which will reduce the number of its outstanding common shares to about 2.9 million from approximately 58.0 million, took effect at the beginning of trading on Thursday.

Shares of OpGen were trading down nearly 18 percent at $2.84 on Thursday morning.

In November, the Rockville, Maryland-based molecular diagnostics firm reported a sharp decline in third quarter revenues, to $448,713 from $1.2 million, as its net loss swelled to $14.1 million, or $.30 per share, from $6.1 million, or $.16 per share, a year ago.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.